---
title: "Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289805471.md"
description: "Traws Pharma (NASDAQ: TRAW) shares dropped 24.09% to $0.97 after the UK regulator deferred its Phase 2a influenza challenge study for tivoxavir marboxil due to a negative review. Despite this setback, the company reaffirmed its commitment to long-acting antiviral strategies and announced it is advancing alternative candidates while maintaining a cash runway through Q1 2027."
datetime: "2026-06-15T15:10:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289805471.md)
  - [en](https://longbridge.com/en/news/289805471.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289805471.md)
generator: "portal-rs"
---

# Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study

**Traws Pharma Inc.** (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.

The decline follows a recent update indicating that the planned Phase 2a human influenza challenge study for its lead compound, tivoxavir marboxil, has been deferred due to a negative review from the UK’s Medicines and Healthcare Products Regulatory Agency.

## TRAW Stock Drops After UK Regulator Delays Influenza Trial

Traws Pharma announced that its lead compound, tivoxavir marboxil, demonstrated efficacy in animal models but has hit a regulatory snag, delaying its clinical trials.

The company remains committed to developing long-acting antiviral therapies, emphasizing the ongoing public health threat posed by influenza.

 **Read Also: Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak** 

## Company Reaffirms Commitment To Long-Acting Antiviral Strategy

“While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority,” said **Robert Redfield,** Chief Medical Officer for Traws Pharma and former Head of the U.S. Centers for Disease Control and Prevention.

“We remain committed to advancing long-acting influenza antivirals and continue to believe this modality has meaningful potential in seasonal influenza prophylaxis. While the recent regulatory feedback affects the timing of our planned challenge study, it does not change our conviction in the underlying scientific rationale. With our cash runway extending to Q1 2027, we are advancing alternative candidates designed to preserve TXM’s pharmacokinetics and efficacy, and exclude potential regulatory concerns,” said **Iain Dukes**, CEO for Traws Pharma.

**TRAW Stock Price Activity:** Traws Pharma shares were down 24.09% at $0.97 at the time of publication on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data.

*Photo: motorolka/Shutterstock*

 **Read Also: Bitcoin Climbs Back Above $65,000, But Expect The True Bottom In Q4, Analyst Says**

### Related Stocks

- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high](https://longbridge.com/en/news/295974913.md)
- [Co-Diagnostics submits FDA 510(k) for Co-Dx PCR Flu A/B & RSV point-of-care test](https://longbridge.com/en/news/296236160.md)
- [16:25 ETAdvance ER Physicians Join Bubble Lounge Podcast to Help Park Cities Families Get Ready for Back-to-School and Cold & Flu Season](https://longbridge.com/en/news/296532991.md)
- [Parkview LaGrange Hospital hosts drive-up flu shot clinic for area residents](https://longbridge.com/en/news/296244642.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**